Risultati per: FDA approva un nuovo trattamento per l’emicrania

New England Journal of Medicine, Ahead of Print.

This cross-sectional study characterizes the frequency and degree of innovation of new dermatologic drugs approved by the US Food and Drug Administration (FDA) from 2012 to 2022.

Caccia nei prodotti bellezza ai Pfas, ‘gli inquinanti eterni’

Fondazione Onda e Anircef insieme per nuovo percorso di cura

Fondazione Onda e Anircef insieme per nuovo percorso di cura

New England Journal of Medicine, Ahead of Print.

To the Editor The proposal to cap nicotine concentrations in combustible cigarettes is based on sound scientific evidence that cigarettes with very low levels of nicotine will significantly reduce smoking- and tobacco-related harm. However, we believe that a proposal presented in a recent Viewpoint for a federal nicotine cap on e-cigarettes is misguided and runs contrary to current evidence. The focus on e-liquid nicotine concentrations alone is problematic because these restrictions fail to consider that e-cigarettes, unlike cigarettes, offer users ways beyond nicotine concentrations to control nicotine delivery, including manipulating device power and compensatory puffing. In fact, the best evidence suggests that this proposed policy would lead to a product that is as addictive as e-cigarettes with higher nicotine concentrations, which may be more appealing to young people, and more harmful.

In Reply We appreciate the Letter by Drs Leavens and Wagener in response to our Viewpoint that raised issues for the US Food and Drug Administration (FDA) to consider as it strives to regulate e-cigarettes.

Tor Vergata è capofila come numero di interventi eseguiti

Il 31 gennaio un incontro alla Camera per avanzare proposte

In 2021, the US saw an estimated 1.6 million chlamydia cases and more than 700 000 gonorrhea cases.

This Viewpoint examines how US states are reforming legislation to allow access to psychedelics for therapeutic use, but federal laws consider these agents to be Schedule I drugs, and the discordance between state and federal law may create confusion and conflict.

The US Food and Drug Administration (FDA) recently greenlit the first vaccine to prevent chikungunya, a disease spread by mosquitos carrying the chikungunya virus. The agency called the virus an “emerging global health threat” due to its growing prevalence and geographic range. The vaccine, marketed as Ixchiq by Valneva Austria GmbH, is approved for adults 18 years or older who are at high risk of exposure to chikungunya virus.

New England Journal of Medicine, Ahead of Print.